The effect of epitope variation on the profile of cytotoxic T lymphocyte responses to the HIV envelope glycoprotein.
To address the relationship between viral and host factors during HIV infection, we analyzed the effect of viral mutations on T cell responses in seropositive, asymptomatic HLA-A2+ individuals using four envelope (env)-specific peptides with the HLA-A*0201 binding motif. We showed that the natural sequence variation was frequent within epitopes located in the C-terminal region of the env glycoprotein and was largely responsible for a lower env-specific cytotoxic T lymphocyte (CTL) activity in the peptide-stimulated cultures. The highest CTL responses in vitro were induced with conserved epitopes D1 and 4.3 that mapped to the N-terminal region of the env glycoprotein. These peptides exhibited high binding affinity for HLA-A*0201 molecules and stimulated CD8+ T cells of relatively limited TCR Vbeta chain repertoire. Decreased CTL activities to the D1 epitope were observed in the absence of any detectable viral mutation, and were associated with lower proliferative responses and expression of the CD28 antigen. Results of this study demonstrate that the degree of sequence variation within a stimulatory epitope of the viral quasispecies, as well as proliferative potential of the effector cells, are among the factors underlying decreased CTL activity in HIV-infected patients. These experiments also provide evidence that the D1 peptide might be useful for the development of vaccines and immune-based therapy.
Kmieciak
D
D
Center for Neurovirology, Department of Neurology, Allegheny University of the Health Sciences, Philadelphia, PA 19102, USA.
Bednarek
I
I
Takiguchi
M
M
Wasik
T J
TJ
Bratosiewicz
J
J
Wierzbicki
A
A
Teppler
H
H
Pientka
J
J
Hsu
S H
SH
Kaneko
Y
Y
Kozbor
D
D
D000328:Adult; D018106:CD28 Antigens / Q000096:biosynthesis; D002460:Cell Line; D003602:Cytotoxicity, Immunologic; D018984:Epitopes, T-Lymphocyte / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D014644:Genetic Variation; D015699:HIV Envelope Protein gp120 / Q000276:immunology* / Q000378:metabolism; D015789:HLA-A2 Antigen / Q000378:metabolism; D006801:Humans; D008213:Lymphocyte Activation / Q000276:immunology*; D011446:Prospective Studies; D011485:Protein Binding / Q000276:immunology; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000235:genetics / Q000276:immunology; D013602:T-Lymphocytes, Cytotoxic / Q000276:immunology* / Q000378:metabolism
D018106:CD28 Antigens; D018984:Epitopes, T-Lymphocyte; D015699:HIV Envelope Protein gp120; D015789:HLA-A2 Antigen; D016693:Receptors, Antigen, T-Cell, alpha-beta